Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 10/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexane SCHEMBL6111434 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| Hexane SCHEMBL77892 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL21899639 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL8517652 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| Hexane SCHEMBL534288 | 1.00 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL14208157 | 0.97 | LMNA (0.52) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL6354364 | 0.97 | LMNA (0.52) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL2344964 | 0.97 | LMNA (0.52) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL2350132 | 0.95 | LMNA (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL2348904 | 0.95 | LMNA (0.50) | SMN1; SMN2LMNAALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757103-B1 | PYRROLIDINE-3-YLACETIC ACID DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2016-01-06 | — | — | EP | disclosed |
| CN-103764648-B | Pyrrolidin-3-yl acetic acid derivatives | EISAI R&D MAN CO LTD | 2015-07-01 | — | — | CN | disclosed |
| EP-2757103-A1 | PYRROLIDINE-3-YLACETIC ACID DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-07-23 | — | — | EP | disclosed |
| CN-103764648-A | Pyrrolidin-3-yl acetic acid derivatives | EISAI R&D MAN CO LTD | 2014-04-30 | — | — | CN | disclosed |
| US-8476301-B2 | Pyrrolidin-3-ylacetic acid derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20130065925-A1 | PYRROLIDIN-3-YLACETIC ACID DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| EP-0599896-A1 | (-) AND (+) 10-(1-AZABICYCLO 2.2.2.]OCT-3-YL-METHYL)-10 H-PHENOTHIAZINE QUATERNARY AMMONIUM DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | Laboratori Guidotti S.p.A. (IT) | 1994-06-08 | — | — | EP | disclosed |
| CN-1071667-A | Phenothiazine quaternary ammonium derivative and process for preparing composition thereof | GUIDOTTI & C SPA LABOR (IT) | 1993-05-05 | — | — | CN | disclosed |
| WO-1993003029-A1 | (-) AND (+) 10-(1-AZABICYCLO[2.2.2.]OCT-3-YL-METHYL)-10 H-PHENOTHIAZINE QUATERNARY AMMONIUM DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | LABORATORI GUIDOTTI S.P.A. (IT) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065925-A1 | PYRROLIDIN-3-YLACETIC ACID DERIVATIVE | CX3CR1, CCR2, CCL2 | SMN1; SMN2 3797/4885LMNA 3912/4885ALDH1A1 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.